The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 +/- 0.31% vs. 0.32 +/- 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 +/- 0.30% vs. 0.27 +/- 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 +/- 0.23% vs. 0.53 +/- 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improved DC maturation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Osada et al., 2008
Citations
Cites
Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A. S., et al. (2000) · Blood · doi:10.1182/blood.v95.3.952.003k27_952_958 · Cited by 2,277 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977 · cited 3×
“Furthermore, high VEGF levels appear to block DC diVerentiation from immature precursors [16].”
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359 · cited 1×
“One mechanism for doing so is the inhibition of DC function [ 5 ].”
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337 · cited 2×
“Because Gabrilovich and colleagues [10, 11] showed that the undiVerentiated hematopoietic cells from cancer patients inhibited the function of fully diVerentiated DC, we hypothesized that administration of anti-VEGF Ab”
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 1×
“studies performed by Gabrilovich, Carbone, and colleagues [10, 28, 29], the presence of increased iMC in cancer patients, which is associated with elevated levels of VEGF, was demonstrated to be involved in mediating DC dysfunction.”
Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 864
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Clinical significance of defective dendritic cell differentiation in cancer.
Almand, B., Resser, J. R., Lindman, B. R., Nadaf, S., Clark, J. I., Kwon, E. D., Carbone, D. P., & Gabrilovich, D. I. (2000) · PubMed · Cited by 699
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596 · cited 1×
“Since PAI-1 is associated with poor prognosis of patients with diVerent types of cancers [24, 25, 30], PAI-1 may have indirect correlation with immunoregulatory DC (DC2).”
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575 · cited 1×
“CECs were deWned as CD45¡/Flk+/CD15¡ and CEPs as CD45¡/Flk+/CD133+ [21, 22].”
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., et al. (2002) · Blood · doi:10.1182/blood.v100.1.230 · Cited by 442 · cited 1×
“Furthermore, the generation of “functionally mature” HLA-DR + DC from CD34 precursors is diminished [8, 9].”
Decreased antigen presentation by dendritic cells in patients with breast cancer.
Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D., & Carbone, D. P. (1997) · PubMed · Cited by 429
VEGF as a Mediator of Tumor-Associated Immunodeficiency
Ohm, J. E., & Carbone, D. P. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:263 · Cited by 371 · cited 1×
“studies performed by Gabrilovich, Carbone, and colleagues [10, 28, 29], the presence of increased iMC in cancer patients, which is associated with elevated levels of VEGF, was demonstrated to be involved in mediating DC dysfunction.”
Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.4.777 · Cited by 314
Immature myeloid cells and cancer-associated immune suppression
Kusmartsev, S., & Gabrilovich, D. I. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0280-8 · Cited by 297 · cited 1×
“Because Gabrilovich and colleagues [10, 11] showed that the undiVerentiated hematopoietic cells from cancer patients inhibited the function of fully diVerentiated DC, we hypothesized that administration of anti-VEGF Ab”
Dendritic Cells in Antitumor Immune Responses
Gabrilovich, D. I., Ciernik, I. F., & Carbone, D. P. (1996) · Cellular Immunology · doi:10.1006/cimm.1996.0139 · Cited by 289 · cited 2×
“DC isolated from tumor-bearing mice [6] and humans [7] have a diminished ability to stimulate T cells.”
Dikov, M. M., Ohm, J. E., Ray, N., Tchekneva, E. E., Burlison, J., Moghanaki, D., Nadaf, S., & Carbone, D. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.215 · Cited by 244
Isolation and characterization of human peripheral blood dendritic cells
Thomas, R., Davis, L. S., & Lipsky, P. E. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.3.821 · Cited by 232 · cited 1×
“To examine if defects in DC maturation persist ex vivo, 1 ml of whole blood was mixed with 9 ml of AIM-V medium (GIBCO, Grand Island, NY) and incubated overnight at 37°C [20].”
Dirix, L. Y., Salgado, R., Weytjens, R., Colpaert, C., Benoy, I., Huget, P., van Dam, P., Prové, A., Lemmens, J., & Vermeulen, P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600069 · Cited by 204
Zeid, N. A., & Konrad Muller, H. (1993) · Pathology · doi:10.3109/00313029309090853 · Cited by 160 · cited 1×
“highlighted by better clinical outcomes for patients with various tumor types when DC are found to be inWltrating the tumor [3, 4].”
Mimura, K., Kono, K., Takahashi, A., Kawaguchi, Y., & Fujii, H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0234-7 · Cited by 138 · cited 1×
“[34] recently reported, using matured human monocyte-derived DC, that VEGF did not aVect DC phenotype, but inhibited allo-stimulatory capacity through VEGFR2 receptor.”
Role of Immature Myeloid Gr-1+ Cells in the Development of Antitumor Immunity
Li, Q., Pan, P.-Y., Gu, P., Xu, D., & Chen, S.-H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1715 · Cited by 135
Blackwell, K., Hurwitz, H. I., Liebérman, G., Novotny, W. F., Snyder, S. A., Dewhirst, M. W., & Greenberg, C. S. (2004) · Cancer · doi:10.1002/cncr.20336 · Cited by 126
Self-citationVEGF-mediated tumour angiogenesis: a new target for cancer therapy
Martiny‐Baron, G., & Marmé, D. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80111-1 · Cited by 124 · cited 1×
“by promoting endothelial cell proliferation [14, 15].”
In vivo maturation and migration of dendritic cells
Flores‐Romo, L. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01204.x · Cited by 115 · cited 1×
“Central to pathways for activating tumor antigen-speciWc T cell and antibody responses is the uptake, processing, and presentation of the tumor antigen by dendritic cells (DC), professional antigen-presenting cells [1, 2].”
Laxmanan, S., Robertson, S. W., Wang, E., Lau, J. S., Briscoe, D. M., & Mukhopadhyay, D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.065 · Cited by 105 · cited 1×
“[33] reported that the direct impairment of DC function by VEGF is mediated primarily by VEGFR1/Flt-1.”
Ma, M., Lyerly, H. K., Gilboa, E., Thomas, E. K., & Sk, N. (1998) · PubMed · Cited by 89
Self-citationCD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer
Coventry, B. J., & Morton, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601114 · Cited by 62
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression
Baker, E. A., Bergin, F. G., & Leaper, D. J. (2000) · Molecular Pathology · doi:10.1136/mp.53.6.307 · Cited by 53 · cited 1×
“Since PAI-1 is associated with poor prognosis of patients with diVerent types of cancers [24, 25, 30], PAI-1 may have indirect correlation with immunoregulatory DC (DC2).”
Mosca, P. J., Hobeika, A. C., Colling, K., Clay, T. M., Thomas, E. K., Caron, D. A., Lyerly, H. K., & Morse, M. A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.3.546 · Cited by 33 · cited 3×
“bottom plate in the medium with CD40-ligand trimer (1 g/ ml; Immunex, Seattle, WA), GM-CSF (Leukine; 800 U/ml; Berlex, Seattle, WA), and Interferon- (ActimmuneTM; 1,000 U/ml; InterMune, Palo Alto, CA) [27].”
Self-citationSchwartz‐Albiez, R., Koretz, K., & Möller, P. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80312-0 · Cited by 21 · cited 1×
“[31] observed that DC within colon cancers strongly expressed u-PA and, at a lower level, also PAI-1.”
Lathers, D. M. R., Lubbers, E., Beal, N. M., Wright, M. A., & Young, M. R. I. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00114-7 · Cited by 10 · cited 1×
“Furthermore, the generation of “functionally mature” HLA-DR + DC from CD34 precursors is diminished [8, 9].”
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.17 · Cited by 953
Metadata
- Authors
- Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., Clay, T., & Morse, M. A.
- Affiliations
- Duke Medical Center (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Hartford Hospital (US)
- Corresponding author
- Morse, Michael A.
- ORCID
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2008-01-10
- Volume
- 57
- Issue
- 8
- Pages
- 1115-1124
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC4110970
- OpenAlex
- W2067969350
- Cited by
- 311
- References
- 35
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 18 · 2021: 30 · 2020: 26 · 2019: 16 · 2018: 24 · 2017: 21 · 2016: 19 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 10
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- National Cancer Institute (K24CA113755, P01CA078673, 5 P01 CA78673.)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- anti-VEGF therapy, bevacizumab, dendritic cells, immature myeloid cells, DC2, dendritic cell maturation, vascular endothelial growth factor, angiogenesis, plasminogen activator inhibitor-1, urokinase, D-dimer, antitumor immunity, lung cancer, breast cancer, colorectal cancer, T cell proliferation
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Breast Neoplasms, Cell Differentiation, Cells, Cultured, Dendritic Cells, Fibrin Fibrinogen Degradation Products, Humans, Immunotherapy, Lung Neoplasms, Neovascularization, Pathologic, Pilot Projects, T-Lymphocytes, Urokinase-Type Plasminogen Activator, Colorectal Neoplasms, Plasminogen Activator Inhibitor 1, Angiogenesis Inhibitors, Myeloid Progenitor Cells, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.